Skip to main content

News

Metformin Lowers Gout Risk in Pre-Diabetes

A large, propensity score-matched cohort study shows that metformin use in patients with pre-diabetes significantly lowers the risk of future gout. 

Biologic-treated Psoriasis has Less Progression to Psoriatic Arthritis

A single center study demonstrates that biologic treatment of psoriasis (PsO) significantly reduces the likelihood of psoriatic arthritis (PsA) development; suggesting a role for more aggressive treatment of PsO. 

ACR Website to Support Primary Care Practitioners

ACR

The American College of Rheumatology recently launched Rheumatology for Primary Care, a new resource for primary care physicians (PCP) and advanced practice providers (APP) offering them expanded support and guid

Hypertension not associated with High NSAID Doses in AxSpA

Medscape
At the recent SPARTAN annual meeting in Cleveland, Dr. Jose Meade-Aguilar reported that amongst axial spondyloarthritis patients receiving nonsteroidal anti-inflammatory drugs, there was no difference in the risk for hypertension when comparing those on high vs. low dose NSAIDs.

No Great Options for Treating VEXAS

MedPage Today

For patients with the auto-inflammatory disease VEXAS, treatment decisions are unfortunately fraught with tradeoffs between effectiveness and risk of adverse effects, a French registry study showed.

The Window of Opportunity (5.24.2024)

Dr. Jack Cush reviews the journal reports and news from the past week on RheumNow.com. This week: blockbuster drugs, opioids in rheumatology and nontreatment of inflammatory arthritis?

Biomarkers Predictive of a Deucravacitinib Response in Psoriatic Arthritis

A phase II trial demonstrating the clinical efficacy of deucravacitinib, a TYK2 inhibitor, in psoriatic arthritis (PsA) suggests specific biologic effects identified by biomarkers may predict clinical responses.

Lupus Research Alliance Grants for Lupus Innovation

EurekAlert!

The Lupus Research Alliance (LRA) is proud to announce that nine international researchers are the recipients of this year’s Lupus Innovation Award (LIA).

Window of Opportunity in Psoriatic Arthritis

The Dutch southwest Early psoriatic arthritis (PsA) cohort study has demonstrated that the earlier the referral and diagnosis of PsA, the better the outcome. 

No Link Between Autoimmune Diseases and Monoclonal Gammopathy of Undetermined Significance

Annals of Internal Medicine reports a study of more than 75,000 persons screened for monoclonal gammopathy of undetermined significance (MGUS) and found no association between autoimmune rheumatic disease (AIRD) and MGUS.

SLE Cost of Care and Disease Activity

A longitudinal, multinational study shows that SLE patients achieving remission or low disease activity incur lower overall direct/indirect (DCs, ICs) healthcare costs than those with persistent activity. 

Upside/Downside of Steroids in Lupus Nephritis

A systematic review of randomized clinical trials of patients with biopsy-proven lupus nephritis (LN) demonstrates both the benefits and harms to early glucocorticoid (GC) regimens on lupus outcomes. 

×